A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

Faye M. Johnson; George R. Blumenschein; Hai T. Tran; Ignacio I. Wistuba; J. Jack Lee; Jeremy J. Erasmus; Jitesh D. Kawedia; Justina Price; Kathryn A. Gold; Nusrat Harun; William N. William; Ximing Tang

首页> 外文期刊>The oncologist >A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

【24h】

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

机译：厄洛替尼和达沙替尼联合治疗非小细胞肺癌的I / II期研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The oncologist》 |2014年第10期|共页
作者
Faye M. Johnson; George R. Blumenschein; Hai T. Tran; Ignacio I. Wistuba; J. Jack Lee; Jeremy J. Erasmus; Jitesh D. Kawedia; Justina Price; Kathryn A. Gold; Nusrat Harun; William N. William; Ximing Tang;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. [J] . Kathryn A Gold, J Jack Lee, Nusrat Harun, The oncologist . 2014,第10期

机译：I / II期研究结合埃洛替尼和达沙替尼治疗非小细胞肺癌。
2. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) [J] . Hai T. Tran, Ralph G. Zinner, George R. Blumenschein Jr., Investigational New Drugs . 2011,第3期

机译：紫杉醇和卡铂联合厄洛替尼或安慰剂治疗晚期非小细胞肺癌（NSCLC）的III期，随机，双盲，多中心试验（TRIBUTE）的药物动力学研究
3. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). [J] . Tran HT, Zinner RG, Blumenschein GR Jr, Investigational new drugs. . 2011,第3期

机译：紫杉醇和卡铂联合厄洛替尼或安慰剂治疗晚期非小细胞肺癌（NSCLC）的III期随机，双盲，多中心试验（TRIBUTE）的药代动力学研究。
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer [O] . Kathryn A. Gold, J. Jack Lee, Nusrat Harun, 2014

机译：埃罗替尼和达沙替尼联合用于非小细胞肺癌的I / II期研究
7. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer [O] . Edward B. Garon, Jill M. Siegfried, Laura P. Stabile, 2018

机译：随机化氨基醛和厄洛替尼的研究与单独的Erlotinib在先进或转移性非小细胞肺癌患者中相比

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

著录项

相似文献

相关主题

期刊订阅